Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 5/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15025402 | 0.89 | CTSS (0.41) | KDM4EALDH1A1ADRB2LOXL2F10 | |
| SCHEMBL624235 | 0.86 | RET (0.46) | KDM4EALDH1A1ADRB2 | |
| SCHEMBL624236 | 0.86 | RET (0.46) | KDM4EALDH1A1ADRB2 | |
| SCHEMBL15025401 | 0.86 | RET (0.46) | KDM4EALDH1A1ADRB2 | |
| SCHEMBL623681 | 0.85 | ROCK2 (0.45) | KDM4EALDH1A1ADRB2LOXL2TSHR | |
| SCHEMBL623675 | 0.85 | ROCK2 (0.45) | KDM4EALDH1A1ADRB2LOXL2TSHR | |
| SCHEMBL623674 | 0.85 | ROCK2 (0.45) | KDM4EALDH1A1ADRB2LOXL2TSHR | |
| SCHEMBL623903 | 0.81 | ALDH1A1 (0.38) | KDM4EALDH1A1ADRB2LOXL2TSHR | |
| SCHEMBL623179 | 0.81 | ALDH1A1 (0.38) | KDM4EALDH1A1ADRB2LOXL2TSHR | |
| SCHEMBL623178 | 0.81 | ALDH1A1 (0.38) | KDM4EALDH1A1ADRB2LOXL2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | claimed |
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC. (JP) | 2013-06-13 | — | — | US | claimed |
| WO-2012020567-A1 | ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-02-16 | — | — | WO | claimed |
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| WO-2012020567-A1 | ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | SCN5A, SCN2A, CACNA1G | KDM4E 1537/4885ALDH1A1 2071/4885ADRB2 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.